Functional genomics in cancer immunotherapy: computational approaches for biomarker and drug discovery

2019 ◽  
Vol 4 (4) ◽  
pp. 689-700 ◽  
Author(s):  
Wee Loong Chin ◽  
Rachael M. Zemek ◽  
W. Joost Lesterhuis ◽  
Timo Lassmann
Keyword(s):  
Drug Discovery ◽  
Functional Genomics ◽  
Cancer Immunotherapy ◽  
Immune Checkpoint ◽  
Biomarker Discovery ◽  
Immune Checkpoint Blockade ◽  
Checkpoint Blockade ◽  
Computational Approaches

A hitchhiker's guide to biomarker discovery in immune checkpoint blockade.

scholarly journals Targeting Metabolism to Control Immune Responses in Cancer and Improve Checkpoint Blockade Immunotherapy

Cancers ◽  
2021 ◽  
Vol 13 (23) ◽  
pp. 5912
Author(s):  
Angèle Luby ◽  
Marie-Clotilde Alves-Guerra
Keyword(s):  
Cancer Immunotherapy ◽  
Immune Cells ◽  
Immune Checkpoint ◽  
Metabolic Pathways ◽  
Cancer Metabolism ◽  
Metabolic Stress ◽  
Immune Checkpoint Blockade ◽  
Checkpoint Blockade ◽  
New Therapeutic Approaches ◽  
Immunosuppressive Tumor Microenvironment

Over the past decade, advances in cancer immunotherapy through PD1–PDL1 and CTLA4 immune checkpoint blockade have revolutionized the management of cancer treatment. However, these treatments are inefficient for many cancers, and unfortunately, few patients respond to these treatments. Indeed, altered metabolic pathways in the tumor play a pivotal role in tumor growth and immune response. Thus, the immunosuppressive tumor microenvironment (TME) reprograms the behavior of immune cells by altering their cellular machinery and nutrient availability to limit antitumor functions. Today, thanks to a better understanding of cancer metabolism, immunometabolism and immune checkpoint evasion, the development of new therapeutic approaches targeting the energy metabolism of cancer or immune cells greatly improve the efficacy of immunotherapy in different cancer models. Herein, we highlight the changes in metabolic pathways that regulate the differentiation of pro- and antitumor immune cells and how TME-induced metabolic stress impedes their antitumor activity. Finally, we propose some drug strategies to target these pathways in the context of cancer immunotherapy.

Potentiation of immune checkpoint blockade cancer immunotherapy with oncolytic virus.

2014 ◽  
Vol 32 (15_suppl) ◽  
pp. 3051-3051 ◽  
Author(s):  
Dmitriy Zamarin ◽  
Rikke Baek Holmgaard ◽  
Sumit Kumar Subudhi ◽  
Joon-Seok Park ◽  
Mena Mansour ◽  
...  
Keyword(s):  
Cancer Immunotherapy ◽  
Immune Checkpoint ◽  
Oncolytic Virus ◽  
Immune Checkpoint Blockade ◽  
Checkpoint Blockade

scholarly journals Cancer immunotherapy — immune checkpoint blockade and associated endocrinopathies

2017 ◽  
Vol 13 (4) ◽  
pp. 195-207 ◽  
Author(s):  
David J. Byun ◽  
Jedd D. Wolchok ◽  
Lynne M. Rosenberg ◽  
Monica Girotra
Keyword(s):  
Cancer Immunotherapy ◽  
Immune Checkpoint ◽  
Immune Checkpoint Blockade ◽  
Checkpoint Blockade

scholarly journals Hybrid Membrane Nanovaccines Combined with Immune Checkpoint Blockade to Enhance Cancer Immunotherapy

2022 ◽  
Vol Volume 17 ◽  
pp. 73-89
Author(s):  
Peiqi Zhao ◽  
Yuanlin Xu ◽  
Wei Ji ◽  
Lanfang Li ◽  
Lihua Qiu ◽  
...  
Keyword(s):  
Cancer Immunotherapy ◽  
Immune Checkpoint ◽  
Immune Checkpoint Blockade ◽  
Hybrid Membrane ◽  
Checkpoint Blockade
Sign in / Sign up

Export Citation Format

Share Document